Johnson & Johnson (NYSE: JNJ) announced on July 23, 2026, positive topline results from the Phase 3 MonumenTAL-6 study, demonstrating that its investigational dual-antigen regimen of TECVAYLI (teclistamab-cqyv) and TALVEY (talquetamab-tgvs) significantly improved survival outcomes in adult patients with relapsed or refractory multiple myeloma (RRMM). The Tec-Tal arm reduced the risk of disease progression or death by 89% and the risk of death by 62%, marking the lowest hazard ratio recorded in any Phase 3 bispecific therapy trial for this condition.

The three-arm study evaluated TECVAYLI plus TALVEY (Tec-Tal) and TALVEY plus pomalidomide (Tal-P) against investigator’s choice of standard care: elotuzumab, pomalidomide, and dexamethasone (EPd) or pomalidomide, bortezomib, and dexamethasone (PVd). Both experimental regimens met the primary endpoint of progression-free survival (PFS). The Tec-Tal arm achieved a hazard ratio (HR) of 0.11 (95% CI, 0.08-0.16; p<0.0001) for progression or death, while the Tal-P arm recorded an HR of 0.27 (95% CI, 0.2-0.35), representing a 73% risk reduction. Due to the strength of the data, the Independent Data Monitoring Committee recommended unblinding the study at the first interim analysis.

Trial Design and Patient Population

MonumenTAL-6 (NCT06208150) is a global, randomized Phase 3 study involving adult patients with RRMM who had received one to four prior lines of therapy, including an anti-CD38 monoclonal antibody and lenalidomide. The primary endpoint was PFS as assessed by an independent review committee. Key secondary endpoints included overall response rate (ORR), complete response or better (≥CR), MRD-negative complete response, and overall survival (OS).

Clinical Significance and Expert Commentary

Ajay K. Nooka, M.D., M.P.H., F.A.C.P., Director of the Myeloma Program at Emory University School of Medicine, noted that the findings reinforce the potential of off-the-shelf immunotherapy doublets in earlier treatment lines. "TECVAYLI and TALVEY together generated deep and durable responses, demonstrating what’s possible by targeting BCMA and GPRC5D at the same time," Nooka said. Yusri Elsayed, M.D., M.H.Sc., Ph.D., Global Therapeutic Area Head of Oncology at Johnson & Johnson, stated that the results strengthen the evidence base for immunotherapy as a cornerstone of multiple myeloma care.

What the Numbers Show

The magnitude of the hazard ratio for the Tec-Tal combination (HR 0.11) indicates a substantial divergence from standard of care outcomes, suggesting that dual-targeting BCMA and GPRC5D may overcome resistance mechanisms often seen with single-antigen therapies. With more than 30,700 patients treated worldwide with TECVAYLI and over 11,000 with TALVEY since their respective approvals, these data support Johnson & Johnson’s strategy of expanding bispecific antibody use into earlier lines of therapy. The safety profiles for both investigational arms were consistent with the known profiles of each monotherapy, with cytokine release syndrome and neurologic toxicity remaining key monitoring parameters under the existing REMS program.

The U.S. Food and Drug Administration granted De Novo authorization for Johnson & Johnson’s OTTAVA Robotic Surgical System, marking the regulatory clearance of the world’s first table-integrated soft tissue robotic platform. The marketing clearance encompasses multiple general surgery procedures. Johnson & Johnson will initiate a commercial rollout with select U.S. facilities, prioritizing initial customer success while working to expand regulatory approvals and procedural indications globally.

The authorization covers procedures including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication, and hiatal hernia repair. An additional U.S. clinical study evaluating the platform for inguinal hernia procedures is currently underway.

Architecture and Space-Saving Design

Built to support modern operating room workflows, OTTAVA incorporates four robotic arms directly into the operating table. The setup reduces the system’s physical footprint by 30% to 50% compared to conventional boom- or cart-mounted robotic systems, giving surgical personnel more space to move, communicate, and deliver care.

Advanced software controls coordinate the table-integrated arms to allow automated procedural setups. A synchronized feature known as Twin motion coordinates table and arm movements simultaneously, enabling patient repositioning and multi-quadrant surgical access without extensive manual adjustments.

Surgical Instruments and Digital Ecosystem

The platform includes updated surgical instrumentation, featuring monopolar curved scissors designed for complete cuts and a specialized two-in-one needle driver engineered to minimize accidental suture damage. To support clinical teams, the system links to the secure Polyphonic digital ecosystem, which consolidates learning materials, media, and data-driven insights.

Additionally, a comprehensive training framework combining virtual, immersive, and hands-on instruction will assist clinicians in adopting the technology safely and effectively. Hani Abouhalka, Company Group Chair, Surgery, MedTech, Johnson & Johnson, emphasized the system's potential to deliver clinical and economic benefits.